{
    "ticker": "ASMB",
    "name": "Assembly Biosciences, Inc.",
    "description": "Assembly Biosciences, Inc. is a clinical-stage biotechnology company focused on the development of innovative therapies for the treatment of viral hepatitis and other liver diseases. Founded in 2015, the company aims to address significant unmet medical needs in the treatment of hepatitis B virus (HBV) infection, a major global health challenge affecting millions of people. Assembly's proprietary platform leverages advanced molecular biology and virology to develop oral therapeutics that target the virus at multiple stages of its life cycle. Their lead product candidates are designed to achieve functional cure for chronic HBV infection, with ongoing clinical trials evaluating their safety and efficacy. In addition to HBV, Assembly is exploring other liver-related diseases and is actively engaged in research collaborations to expand its pipeline. With a dedicated team of scientists and industry veterans, Assembly is committed to advancing its innovative programs and delivering transformative therapies to patients. The company\u2019s approach emphasizes a strong scientific foundation and rigorous clinical development, positioning it as a leader in the fight against viral hepatitis and related liver conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Francisco, California, USA",
    "founded": "2015",
    "website": "https://www.assemblybio.com",
    "ceo": "John McHutchison",
    "social_media": {
        "twitter": "https://twitter.com/AssemblyBio",
        "linkedin": "https://www.linkedin.com/company/assembly-biosciences"
    },
    "investor_relations": "https://investors.assemblybio.com",
    "key_executives": [
        {
            "name": "John McHutchison",
            "position": "CEO"
        },
        {
            "name": "David A. H. Wiggins",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "ABI-H0731",
                "ABI-H2158"
            ]
        }
    ],
    "seo": {
        "meta_title": "Assembly Biosciences, Inc. | Innovative Therapies for Viral Hepatitis",
        "meta_description": "Explore Assembly Biosciences, Inc., a leader in the development of innovative therapies for viral hepatitis and liver diseases. Learn about their clinical-stage programs and commitment to patient care.",
        "keywords": [
            "Assembly Biosciences",
            "Hepatitis B",
            "Biotechnology",
            "Liver Diseases",
            "Viral Hepatitis",
            "ABI-H0731"
        ]
    },
    "faq": [
        {
            "question": "What is Assembly Biosciences focused on?",
            "answer": "Assembly Biosciences focuses on developing innovative therapies for the treatment of viral hepatitis and liver diseases."
        },
        {
            "question": "Who is the CEO of Assembly Biosciences?",
            "answer": "John McHutchison is the CEO of Assembly Biosciences, Inc."
        },
        {
            "question": "Where is Assembly Biosciences headquartered?",
            "answer": "Assembly Biosciences is headquartered in San Francisco, California, USA."
        },
        {
            "question": "What are Assembly Biosciences' main products?",
            "answer": "Assembly Biosciences' main products include ABI-H0731 and ABI-H2158, which are focused on treating hepatitis B."
        },
        {
            "question": "When was Assembly Biosciences founded?",
            "answer": "Assembly Biosciences was founded in 2015."
        }
    ],
    "competitors": [
        "GILD",
        "ABBV",
        "BMY"
    ],
    "related_stocks": [
        "VRTX",
        "REGN",
        "AMGN",
        "BIIB"
    ]
}